BIBvsSPDW
ProShares Ultra Nasdaq Biotechnology against SPDR Portfolio Developed World ex-US ETF — the fee, the flows, the book, and a year head-to-head.
Head to head
| BIB | SPDW | |
|---|---|---|
| Expense ratio | 0.95% | 0.030% |
| Assets | $96M | $40.7B |
| Net flow, 1 month | +$2M | +$609M |
| Net flow, 1 year | −$8M | +$4.8B |
| Return, YTD | +39.2% | +10.9% |
| Return, 1 year | — | — |
| Avg daily volume | 8K | 3M |
| Holdings | 229 | 2480 |
| Listed | Apr 9, 2010 | Apr 20, 2007 |
| Options market | Yes | Yes |
MARKED CELLS LEAD ON THAT LINE · LOWER FEE, LARGER ASSETS, STRONGER FLOWS & RETURNS